Century Therapeutics presents preclinical data for CNTY-813; glucose control >8 months, IND on track for Q4 2026

Century Therapeutics, Inc.

CNTY-813 maintained glucose control for >8 months in diabetic mouse models without immunosuppression.
No tumorigenesis observed in >140 mice with >1 billion cells infused over 3 months follow-up.
Allo-Evasion 5.0 edits provided protection from NK cells, antibody-mediated phagocytosis, and maintained insulin secretion in humanized mouse model.
Phase 1 manufacturing process established; consistent product quality across 11 samples from GMP Master Cell Bank.
IND submission on track for Q4 2026; initial clinical data expected in 2H 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.